Trastuzumab: 9 agencies, 2006–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil) has been easier on trastuzumab than on its own caseload: it refused 0 of 5 decisive submissions here (0%), against a base rate of 44% across everything it has assessed.
The file has been open for more than a decade: 19.8 years separate the first record, 4 Oct 2006 at HAS (France), from the most recent, 2026 at PBAC (Australia).
CIPM (Spain) changed its position: not recommended on 16 Dec 2021, recommended by 2 Mar 2023, after a resubmission.
No assessment is on file from TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for trastuzumab, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 7 of 57 records date from 2023 or later.
The programme is broad: 14 distinct indication wordings are recorded for trastuzumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
15 of these 57 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess trastuzumab, on 4 Oct 2006; CIPM (Spain) did not open a file until 16 Dec 2021 — an unusually long tail of 15.2 years between the earliest and latest system to look at it.
The record arrives in waves: 13 separate years each carry two or more decisions, spread across 20 years in total.
8 of the 9 agencies here assessed trastuzumab more than once, HAS (France) most often at 17 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for trastuzumab.
The full ledger for trastuzumab reads 37 recommended, 12 not recommended, 2 deferred and 2 restricted, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Gastric or gastroesophageal junction (G/GOJ) cancer | Deferred | source |
| CONITEC (Brazil) | 15 May 2025 | Tratamento de adultos com câncer de estômago ou da junção esofagogástrica, avançado ou metastático, HER2+ e não tratados… | incorporated into SUS | source |
| PHARMAC (New Zealand) | 28 Mar 2024 | Breast cancer-treatment beyond disease progression | PTAC advice: Decline | source |
| CIPM (Spain) | 2 Mar 2023 | SECRETARIA DE ESTADO DE SANIDAD 22 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicaciones terapéuticas autorizadas: Cá… | financed by the SNS, on appeal · art. 92 a, d | source |
| HAS (France) | 4 Sep 2019 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
52 further decisions for trastuzumab, across 9 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 27 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 57 decisions for trastuzumab from 9 agencies, 2006 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.